The tweet was deleted by the author.
But we saved everything 🙂.
Editas Medicine announced that its President and CEO, Gilmore O’Neill, will participate in the upcoming Longwood Healthcare Leaders MIT CEO 2026 Meeting. He is scheduled to join industry peers for a panel discussion focused on pipeline prioritization within the biotechnology sector.
The event will bring together leading executives to examine strategic approaches to advancing research and development priorities. Editas Medicine aims to contribute insights on decision-making and resource allocation in biotech pipelines.
Earlier this year, Editas Medicine revised its presentation timing for an investor conference and provided additional details in a press release here. The company also revealed new preclinical results for its gene editing candidate EDIT-401 at EASCongress2026 here. Both events highlight Editas Medicine's recent activity in sharing research and company updates with stakeholders.